Synteract acquires KinderPharm to be ‘one-stop shop’ for pediatric clinical trials

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/KatarzynaBialasiewicz)
(Image: Getty/KatarzynaBialasiewicz)

Related tags: Synteract, KinderPharm, Pediatrics, Drug development, Clinical trials

Synteract’s clients will benefit from a single source model, says CEO, following the acquisition of KinderPharm, a PA-based CRO focused on all phases of pediatric drug development.

Synteract CEO Steve Powell said the combined contract research organization (CRO) will offer biopharma a “one-stop shop solution for bringing their pediatric clinical trials​ to life.”

“Through the KinderPharm integration, our clients will be able to benefit from a single source model,” ​Powell told us.

The single source model will offer pharmacometric modeling and clinical trial simulation technologies, including pharmacokinetic data analysis, PK/PD modeling, physiologically-based PK modeling, and population PK analysis.

Powell added, “KinderPharm also brings a focus on the development of novel and rare pediatric drugs through pediatric formulation and juvenile toxicology expertise, as well as extensive US and European pediatric regulatory experience.”

Martin Graham, PhD, KinderPharm CEO and founder, will join the team as senior vice president of pediatric development, leading Synteract’s Center of Pediatric Development. 

Graham will be joined by KinderPharm’s Lynne Georgopoulos, vice president pediatric development, Americas, and Synteract’s Dr. Martine Dehlinger-Kremer, vice president pediatric development, Europe, to build a leadership team.

Synteract earlier this year announced​ pediatrics as one of its “therapeutic centers of development.”​ Other centers include oncology, neuro-degenerative disorders, rare and orphan diseases, as well as dermatology – following the acquisition​ of Cu-Tech in July.

KinderPharm was previously involved in a strategic alliance with Worldwide Clinical Trials​ (WCT). Announced in April of this year, the alliance established a center of excellence for pediatric drug development and research. The relationship had since been dissolved.

Related news

Show more

Related products

show more

Flow Cytometry Services

Flow Cytometry Services

Q2 Solutions | 01-Jun-2020 | Data Sheet

We are an established leader in flow cytometry services for clinical trials. Our technologies and solutions meet the growing global demand for enhanced...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Related suppliers

Follow us


View more